{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:39:55Z","timestamp":1778945995103,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1186\/s12859-019-2628-5","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T13:03:24Z","timestamp":1552568604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA"],"prefix":"10.1186","volume":"20","author":[{"given":"Leihong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zhao-Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junshuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshan","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weigong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weida","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"issue":"15","key":"2628_CR1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200\u20135.","journal-title":"Jama"},{"key":"2628_CR2","unstructured":"Code of Federal Regulations Title 21 (21CFR) 312.32 [ https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=312.32 ], accessed on 03\/2018."},{"issue":"2","key":"2628_CR3","first-page":"65","volume":"13","author":"P D'arcy","year":"1993","unstructured":"D'arcy P, Griffin J. Thalidomide revisited. Adverse Drug React Toxicol Rev. 1993;13(2):65\u201376.","journal-title":"Adverse Drug React Toxicol Rev"},{"issue":"9237","key":"2628_CR4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"issue":"7456","key":"2628_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj. 2004;329(7456):15\u20139.","journal-title":"Bmj"},{"issue":"6","key":"2628_CR6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMe0708842","volume":"358","author":"M Ingelman-Sundberg","year":"2008","unstructured":"Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med. 2008;358(6):637\u20139.","journal-title":"N Engl J Med"},{"issue":"21","key":"2628_CR7","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","volume":"365","author":"DS Budnitz","year":"2011","unstructured":"Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002\u201312.","journal-title":"N Engl J Med"},{"issue":"7","key":"2628_CR8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/pds.2155","volume":"20","author":"ZP Qureshi","year":"2011","unstructured":"Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011;20(7):772\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2628_CR9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","volume":"16","author":"MT Smith","year":"2003","unstructured":"Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol. 2003;16(6):679\u201387.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"2628_CR10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1572-0241.2000.01707.x","volume":"95","author":"J Kohlroser","year":"2000","unstructured":"Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 2000;95(1):272\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2628_CR11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14740338.6.6.673","volume":"6","author":"SH Hussaini","year":"2007","unstructured":"Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6(6):673\u201384.","journal-title":"Expert Opin Drug Saf"},{"key":"2628_CR12","doi-asserted-by":"crossref","unstructured":"Code of Federal Regulations Title 21 (21CFR) 201.57 [ https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?fr=201.57 ], accessed on 03\/2018.","DOI":"10.1055\/s-0043-124391"},{"issue":"10","key":"2628_CR13","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.drudis.2016.06.006","volume":"21","author":"H Fang","year":"2016","unstructured":"Fang H, Harris SC, Liu Z, Zhou G, Zhang G, Xu J, Rosario L, Howard PC, Tong W. FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science. Drug Discov Today. 2016;21(10):1566\u201370.","journal-title":"Drug Discov Today"},{"issue":"15","key":"2628_CR14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","volume":"16","author":"M Chen","year":"2011","unstructured":"Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15):697\u2013703.","journal-title":"Drug Discov Today"},{"issue":"2","key":"2628_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"2","key":"2628_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03256752","volume":"23","author":"P Mozzicato","year":"2009","unstructured":"Mozzicato P. MedDRA - an overview of the medical dictionary or regulatory activities. Pharmaceutical Medicine. 2009;23(2):65\u201375.","journal-title":"Pharmaceutical Medicine"},{"key":"2628_CR17","unstructured":"Mozzicato P. MedDRA - past and future. Regulatory Affairs J Pharma. 2006:797\u2013805."},{"key":"2628_CR18","unstructured":"Harrison J, Zhao-Wong A. Working with MedDRA to improve data standards. Good Clinical Practice Journal. 2006."},{"key":"2628_CR19","doi-asserted-by":"crossref","unstructured":"Tabor E. Cobert\u2019s manual of drug safety and Pharmacovigilance. Drug Information Journal. 2012;46(1):140\u20130.","DOI":"10.1177\/0092861511427860"},{"issue":"7","key":"2628_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40264-016-0414-0","volume":"39","author":"S Sarntivijai","year":"2016","unstructured":"Sarntivijai S, Zhang S, Jagannathan DG, Zaman S, Burkhart KK, Omenn GS, He Y, Athey BD, Abernethy DR. Linking MedDRA\u00ae. Drug Saf. 2016;39(7):697\u2013707.","journal-title":"Drug Saf"},{"issue":"8","key":"2628_CR21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","volume":"28","author":"F Thiessard","year":"2005","unstructured":"Thiessard F, Roux E, Miremont-Salam\u00e9 G, Fourrier-R\u00e9glat A, Haramburu F, Tubert-Bitter P, B\u00e9gaud B. Trends in spontaneous adverse drug reaction reports to the French Pharmacovigilance system (1986\u20142001). Drug Saf. 2005;28(8):731\u201340.","journal-title":"Drug Saf"},{"key":"2628_CR22","doi-asserted-by":"crossref","unstructured":"de Langen J, van Hunsel F, Passier A, de Jong-van den berg L, van Grootheest K: Adverse drug reaction reporting by patients in the Netherlands three years of experience. Drug Saf 2008, 31(6):515\u2013524.","DOI":"10.2165\/00002018-200831060-00006"},{"issue":"9","key":"2628_CR23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/11536510-000000000-00000","volume":"33","author":"DJ McLernon","year":"2010","unstructured":"McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A, Collaboration YC. Adverse drug reaction reporting in the Uk. Drug Saf. 2010;33(9):775\u201388.","journal-title":"Drug Saf"},{"issue":"1","key":"2628_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/11594320-000000000-00000","volume":"35","author":"F Hunsel van","year":"2012","unstructured":"van Hunsel F, H\u00e4rmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients. Drug Saf. 2012;35(1):45\u201360.","journal-title":"Drug Saf"},{"key":"2628_CR25","doi-asserted-by":"crossref","unstructured":"Nikfarjam A, Sarker A, O\u2019Connor K, Ginn R, Gonzalez G: Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc 2015:ocu041.","DOI":"10.1093\/jamia\/ocu041"},{"key":"2628_CR26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jbi.2015.02.004","volume":"54","author":"A Sarker","year":"2015","unstructured":"Sarker A, Ginn R, Nikfarjam A, O\u2019Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez G. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015;54:202\u201312.","journal-title":"J Biomed Inform"},{"key":"2628_CR27","doi-asserted-by":"crossref","unstructured":"Segura-Bedmar I, De La Pe\u00f1a S, Mart\u0131nez P. Extracting drug indications and adverse drug reactions from Spanish health social media. Proceedings of BioNLP. 2014:98\u2013106.","DOI":"10.3115\/v1\/W14-3415"},{"issue":"2","key":"2628_CR28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0165551515625029","volume":"43","author":"X Ji","year":"2017","unstructured":"Ji X, Chun SA, Cappellari P, Geller J. Linking and using social media data for enhancing public health analytics. J Inf Sci. 2017;43(2):221\u201345.","journal-title":"J Inf Sci"},{"issue":"10","key":"2628_CR29","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1471-2105-12-S10-S11","volume":"12","author":"H Bisgin","year":"2011","unstructured":"Bisgin H, Liu Z, Fang H, Xu X, Tong W. Mining FDA drug labels using an unsupervised learning technique-topic modeling. BMC bioinformatics. 2011;12(10):S11.","journal-title":"BMC bioinformatics"},{"issue":"1","key":"2628_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/msb.2009.98","volume":"6","author":"M Kuhn","year":"2010","unstructured":"Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010;6(1):343.","journal-title":"Mol Syst Biol"},{"issue":"5886","key":"2628_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1158140","volume":"321","author":"M Campillos","year":"2008","unstructured":"Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321(5886):263\u20136.","journal-title":"Science"},{"issue":"D1","key":"2628_CR32","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44(D1):D1075\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2628_CR33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1471-2105-15-267","volume":"15","author":"H Bisgin","year":"2014","unstructured":"Bisgin H, Liu Z, Fang H, Kelly R, Xu X, Tong W. A phenome-guided drug repositioning through a latent variable model. BMC bioinformatics. 2014;15(1):267.","journal-title":"BMC bioinformatics"},{"issue":"5","key":"2628_CR34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.2013.16","volume":"93","author":"M Chen","year":"2013","unstructured":"Chen M, Zhang J, Wang Y, Liu Z, Kelly R, Zhou G, Fang H, Borlak J, Tong W. The liver toxicity knowledge base: a systems approach to a complex end point. Clinical Pharmacology & Therapeutics. 2013;93(5):409\u201312.","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"4","key":"2628_CR35","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21(4):648\u201353.","journal-title":"Drug Discov Today"},{"issue":"10","key":"2628_CR36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tips.2017.06.005","volume":"38","author":"Z Liu","year":"2017","unstructured":"Liu Z, Delavan B, Roberts R, Tong W. Lessons learned from two decades of anticancer drugs. Trends Pharmacol Sci. 2017;38(10):852\u201372.","journal-title":"Trends Pharmacol Sci"},{"key":"2628_CR37","doi-asserted-by":"crossref","unstructured":"Blendon RJ, Benson JM. The public and the opioid-abuse epidemic. N Engl J Med. 2018.","DOI":"10.1056\/NEJMp1714529"},{"key":"2628_CR38","unstructured":"Risk Evaluation and Mitigation Strategies (REMS) https:\/\/www.fda.gov\/Drugs\/DrugSafety\/REMS\/default.htm , accessed on 03\/2018."},{"key":"2628_CR39","first-page":"279","volume":"121","author":"K Donnelly","year":"2006","unstructured":"Donnelly K. SNOMED-CT: the advanced terminology and coding system for eHealth. Studies in health technology and informatics. 2006;121:279.","journal-title":"Studies in health technology and informatics"},{"key":"2628_CR40","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2018.1","volume":"5","author":"D Demner-Fushman","year":"2018","unstructured":"Demner-Fushman D, Shooshan SE, Rodriguez L, Aronson AR, Lang F, Rogers W, Roberts K, Tonning J. A dataset of 200 structured product labels annotated for adverse drug reactions. Scientific data. 2018;5:180001.","journal-title":"Scientific data"},{"issue":"3","key":"2628_CR41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/JCP.0b013e318218f3e4","volume":"31","author":"J Leon de","year":"2011","unstructured":"de Leon J. Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol. 2011;31(3):263\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2628_CR42","first-page":"11","volume":"24","author":"P Dixon","year":"2001","unstructured":"Dixon P. Basics of oracle text retrieval. IEEE Data Eng Bull. 2001;24(4):11\u20134.","journal-title":"IEEE Data Eng Bull"},{"key":"2628_CR43","doi-asserted-by":"crossref","unstructured":"Murthy R, Banerjee S: Xml schemas in Oracle XML DB. In: Proceedings of the 29th international conference on Very large data bases-Volume 29: 2003. VLDB Endowment: 1009\u20131018.","DOI":"10.1016\/B978-012722442-8\/50094-X"},{"issue":"suppl 1","key":"2628_CR44","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(suppl 1):D668\u201372.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2628_CR45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1012801612483","volume":"17","author":"M Halkidi","year":"2001","unstructured":"Halkidi M, Batistakis Y, Vazirgiannis M. On clustering validation techniques. J Intell Inf Syst. 2001;17(2):107\u201345.","journal-title":"J Intell Inf Syst"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-2628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-019-2628-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-2628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T20:24:18Z","timestamp":1663100658000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-019-2628-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":45,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2628"],"URL":"https:\/\/doi.org\/10.1186\/s12859-019-2628-5","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"14 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"97"}}